Depletion or inactivation of B cells at the early stages of AD pathology in transgenic AD mice has demonstrated beneficial therapeutic impact by restoring TGF-β+ microglia, which have enhanced ability to clear Aβ oligomers and slow down the progression of AD. Here, TGFB1 is linked to Alzheimer disease.